S Agarwal1,2, R M Ahmed2, M D'Mello3,4, D Foxe3,4,5, C Kaizik2,5, M C Kiernan2, G M Halliday2,3,5, O Piguet3,4,5, J R Hodges2,4. 1. Neurology Unit, Addenbrooke's Hospital, Cambridge, UK. 2. Central Clinical School and Brain and Mind Centre, The University of Sydney, Sydney, New South Wales. 3. School of Psychology and Brain and Mind Centre, The University of Sydney, Sydney, New South Wales. 4. ARC Centre of Excellence in Cognition and its Disorders, Sydney, New South Wales. 5. Neuroscience Research Australia (NeuRA), University of New South Wales, Sydney, New South Wales, Australia.
Abstract
BACKGROUND AND PURPOSE: Predicting the course of behavioural variant frontotemporal dementia (bvFTD) remains a major clinical challenge. This study aimed to identify factors that predict survival and clinical progression in bvFTD. METHODS: Consecutive patients with clinically probable bvFTD were prospectively followed up over an 8-year period. Baseline neuropsychological variables, presence of a known pathogenic frontotemporal dementia gene mutation and a systematic visual magnetic resonance imaging assessment at baseline were examined as candidate predictors using multivariate modelling. RESULTS: After screening 121 cases, the study cohort consisted of 75 patients with probable bvFTD, with a mean age of 60.8 ± 8.5 years, followed up for a mean duration of 7.2 ± 3.5 years from symptom onset. Median survival time from disease onset was 10.8 years and median survival, prior to transition to nursing home, was 8.9 years. A total of 25 of the 75 patients died during the study follow-up period. Survival without dependence was predicted by shorter disease duration at presentation (hazard ratio, 0.49, P = 0.001), greater atrophy in the anterior cingulate cortex (hazard ratio, 1.75, P = 0.047), older age (hazard ratio, 1.07, P = 0.026) and a higher burden of behavioural symptoms (hazard ratio, 1.04, P = 0.015). In terms of disease progression, presence of a known pathogenic frontotemporal dementia mutation (β = 0.46, P < 0.001) was the strongest predictor of progression. Deficits in letter fluency (β = -0.43, P = 0.017) and greater atrophy in the motor cortex (β = 0.51, P = 0.03) were also associated with faster progression. CONCLUSIONS: This study provides novel clinical predictors of survival and progression in bvFTD. Our findings are likely to have an impact on prognostication and care planning in this difficult disease.
BACKGROUND AND PURPOSE: Predicting the course of behavioural variant frontotemporal dementia (bvFTD) remains a major clinical challenge. This study aimed to identify factors that predict survival and clinical progression in bvFTD. METHODS: Consecutive patients with clinically probable bvFTD were prospectively followed up over an 8-year period. Baseline neuropsychological variables, presence of a known pathogenic frontotemporal dementia gene mutation and a systematic visual magnetic resonance imaging assessment at baseline were examined as candidate predictors using multivariate modelling. RESULTS: After screening 121 cases, the study cohort consisted of 75 patients with probable bvFTD, with a mean age of 60.8 ± 8.5 years, followed up for a mean duration of 7.2 ± 3.5 years from symptom onset. Median survival time from disease onset was 10.8 years and median survival, prior to transition to nursing home, was 8.9 years. A total of 25 of the 75 patients died during the study follow-up period. Survival without dependence was predicted by shorter disease duration at presentation (hazard ratio, 0.49, P = 0.001), greater atrophy in the anterior cingulate cortex (hazard ratio, 1.75, P = 0.047), older age (hazard ratio, 1.07, P = 0.026) and a higher burden of behavioural symptoms (hazard ratio, 1.04, P = 0.015). In terms of disease progression, presence of a known pathogenic frontotemporal dementia mutation (β = 0.46, P < 0.001) was the strongest predictor of progression. Deficits in letter fluency (β = -0.43, P = 0.017) and greater atrophy in the motor cortex (β = 0.51, P = 0.03) were also associated with faster progression. CONCLUSIONS: This study provides novel clinical predictors of survival and progression in bvFTD. Our findings are likely to have an impact on prognostication and care planning in this difficult disease.
Authors: Na-Yeon Jung; Kee Hyung Park; Sang Won Seo; Hee Jin Kim; Jee Hoon Roh; Jae-Hong Lee; Kyung Won Park; Jay C Kwon; Jee Hyang Jeong; Soo Jin Yoon; Byeong C Kim; Young Ho Park; SangYun Kim; Jae-Won Jang; Young Chul Youn; Dong Won Yang; Seong Hye Choi; Duk L Na; Eun-Joo Kim Journal: J Clin Med Date: 2022-04-18 Impact factor: 4.964
Authors: Carrie Caswell; Corey T McMillan; Sharon X Xie; Vivianna M Van Deerlin; EunRan Suh; Edward B Lee; John Q Trojanowski; Virginia M-Y Lee; David J Irwin; Murray Grossman; Lauren M Massimo Journal: Neurology Date: 2019-09-19 Impact factor: 9.910
Authors: Jay L P Fieldhouse; Flora T Gossink; Thomas C Feenstra; Sterre C M de Boer; Afina W Lemstra; Niels D Prins; Femke Bouwman; Ted Koene; Hanneke F M Rhodius-Meester; Freek Gillissen; Charlotte E Teunissen; Wiesje M van der Flier; Philip Scheltens; Annemieke Dols; Everard G B Vijverberg; Yolande A L Pijnenburg Journal: J Alzheimers Dis Date: 2021 Impact factor: 4.472
Authors: Alberto Benussi; Enrico Premi; Stefano Gazzina; Chiara Brattini; Elisa Bonomi; Antonella Alberici; Lize Jiskoot; John C van Swieten; Raquel Sanchez-Valle; Fermin Moreno; Robert Laforce; Caroline Graff; Matthis Synofzik; Daniela Galimberti; Mario Masellis; Carmela Tartaglia; James B Rowe; Elizabeth Finger; Rik Vandenberghe; Alexandre de Mendonça; Fabrizio Tagliavini; Isabel Santana; Simon Ducharme; Chris R Butler; Alexander Gerhard; Johannes Levin; Adrian Danek; Markus Otto; Giovanni Frisoni; Roberta Ghidoni; Sandro Sorbi; Isabelle Le Ber; Florence Pasquier; Georgia Peakman; Emily Todd; Martina Bocchetta; Jonathan D Rohrer; Barbara Borroni Journal: JAMA Netw Open Date: 2021-01-04
Authors: Ignacio Illán-Gala; Kaitlin B Casaletto; Sergi Borrego-Écija; Eider M Arenaza-Urquijo; Amy Wolf; Yann Cobigo; Sheng Yang M Goh; Adam M Staffaroni; Daniel Alcolea; Juan Fortea; Rafael Blesa; Jordi Clarimon; Maria Florencia Iulita; Anna Brugulat-Serrat; Albert Lladó; Lea T Grinberg; Katherine Possin; Katherine P Rankin; Joel H Kramer; Gil D Rabinovici; Adam Boxer; William W Seeley; Virginia E Sturm; Maria Luisa Gorno-Tempini; Bruce L Miller; Raquel Sánchez-Valle; David C Perry; Alberto Lleó; Howard J Rosen Journal: Alzheimers Dement Date: 2021-02-16 Impact factor: 16.655
Authors: Alexander G Murley; Matthew A Rouse; Ian T S Coyle-Gilchrist; P Simon Jones; Win Li; Julie Wiggins; Claire Lansdall; Patricia Vázquez Rodríguez; Alicia Wilcox; Karalyn Patterson; James B Rowe Journal: J Neurol Neurosurg Psychiatry Date: 2021-02-09 Impact factor: 13.654
Authors: Alexander G Murley; Matthew A Rouse; P Simon Jones; Rong Ye; Frank H Hezemans; Claire O'Callaghan; Polytimi Frangou; Zoe Kourtzi; Catarina Rua; T Adrian Carpenter; Christopher T Rodgers; James B Rowe Journal: Brain Date: 2020-12-05 Impact factor: 13.501